Vaccine therapy for cancer: fact or fiction? 2004

Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.

Great strides in the understanding of regulation of the immune system have led to development of strategies to harness the potential of cellular immune responses for improving the outcome for cancer patients. To generate a cytotoxic T-lymphocyte (CTL) response to cancer cells requires tumor-specific antigens processed appropriately and displayed by major histocompatibility complex (MHC) molecules, T-lymphocytes with receptors of appropriate specificity, and co-stimulation delivered by antigen-presenting cells through members of the B7 family. In this review, the fundamental advances that have been made in tumor antigen discovery, and the novel vaccine approaches arising from these advances are discussed.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005544 Forecasting The prediction or projection of the nature of future problems or existing conditions based upon the extrapolation or interpretation of existing scientific data or by the application of scientific methodology. Futurology,Projections and Predictions,Future,Predictions and Projections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D016233 Immunotherapy, Active Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system. Immune RNA Manipulation,Vaccine Therapy,Active Immunotherapy,Therapy, Vaccine,Active Immunotherapies,Immune RNA Manipulations,Immunotherapies, Active,Manipulation, Immune RNA,Manipulations, Immune RNA,RNA Manipulation, Immune,RNA Manipulations, Immune,Therapies, Vaccine,Vaccine Therapies

Related Publications

Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
June 1999, QJM : monthly journal of the Association of Physicians,
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
January 2010, Urologic oncology,
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
January 2012, The Journal of IMA,
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
December 2014, Future oncology (London, England),
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
April 2015, Journal of fungi (Basel, Switzerland),
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
May 2013, Comparative immunology, microbiology and infectious diseases,
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
December 1997, Gut,
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
July 2021, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation,
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
October 1968, Texas medicine,
Kunle Odunsi, and Shashikant Lele, and Raghu Savalgi
June 2006, Current sports medicine reports,
Copied contents to your clipboard!